Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study.

Abstract

Purpose: To compare alcaftadine and olopatadine ophthalmic solutions, and vehicle for preventing allergen-mediated conjunctivitis in Japanese subjects. Methods: Japanese cedar pollen-sensitive subjects were randomized to alcaftadine 0.25%, olopatadine 0.1%, or vehicle. Ocular itching was assessed at 3, 5 (primary outcome), 7, and 15 min post-conjunctival allergen challenge (CAC) and conjunctival hyperemia assessed at 7, 15 (secondary outcome), and 20 min post-CAC. Adverse events were monitored. Results: Overall, 240 subjects were randomized. Alcaftadine 0.25% (challenged 8 h post-dose) was significantly more effective than vehicle for prevention of itching and conjunctival hyperemia (p < 0.001) and noninferior to olopatadine 0.1% (challenged 4 h post-dose). Significantly lower hyperemia scores were observed in alcaftadine-treated than olopatadine-treated eyes at 7 and 15 min post-CAC (p ≤ 0.027). Alcaftadine and olopatadine were well tolerated; no serious adverse events were reported. Conclusion: Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis.

• Authors: Hiroshi Nakatani, Paul Gomes, Ron Bradford, Qiang Guo, Eleonora Safyan, David A Hollander
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 27 Issue 4 Pg. 622-631 ( 2019) ISSN: 1744-5078 [Electronic] England
• PMID: 29543548 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzazepines
• Histamine H1 Antagonists
• Imidazoles
• Ophthalmic Solutions
• Olopatadine Hydrochloride
• alcaftadine

Topics

• Adult
• Benzazepines (administration & dosage)
• Cedrus (adverse effects)
• Conjunctivitis, Allergic (epidemiology, prevention & control)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Follow-Up Studies
• Histamine H1 Antagonists (administration & dosage)
• Humans
• Imidazoles (administration & dosage)
• Incidence
• Japan (epidemiology)
• Male
• Olopatadine Hydrochloride (administration & dosage)
• Ophthalmic Solutions (administration & dosage)
• Pollen (adverse effects)
• Retrospective Studies
• Seasons
• Treatment Outcome